| 代码 | 名称 | 主力净流入 (元) | | | | 主力净占比 游资净流入 (元) 游资净占比 散户净流入 (元) 散户净占比 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 920982 锦波生物 | | | 777.78万 | 4.57% | -145.86万 | -0.86% | 838.00 | 0.00% | | 688363 华熙生物 | | | 486.39万 | 2.47% | -2118.96万 | -10.76% | 1632.57万 | 8.29% | | 000615 *ST美谷 | | | -501.91万 | -21.98% | 111.70万 | 4.89% | 390.21万 | 17.09% | | 300896 | 爱美客 | | -567.61万 | -1.31% | -1527.19万 | -3.53% | 2094.79万 | 4.84% | 证券之星消息，1月23日医疗美容板块较上一交易日上涨1.5%，华熙生物领涨。当日上证指数报收于 4136.16，上涨0.33%。深证成指报收 ...

Investment Rating - The report gives a "Market Weight" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [26]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 0.75% from January 9 to January 22, 2026, which is approximately 0.46 percentage points lower than the CSI 300 index [11]. - Most sub-sectors within the industry recorded positive returns during the same period, with offline pharmacies and raw materials sectors leading with increases of 3.14% and 2.34%, respectively [12]. - Approximately 66% of stocks in the industry recorded positive returns, with the top performer, Baolait, seeing a weekly increase of 60.88% [13]. - The overall price-to-earnings (P/E) ratio for the SW pharmaceutical and biotechnology industry was approximately 52.01 times as of January 22, 2026, showing little change [19]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry lagged behind the CSI 300 index, with a decline of 0.75% from January 9 to January 22, 2026 [11]. - Most sub-sectors achieved positive returns, particularly offline pharmacies and raw materials, which rose by 3.14% and 2.34% respectively [12]. - About 66% of stocks in the industry had positive returns, with Baolait leading at a 60.88% increase [13]. - The industry’s P/E ratio was approximately 52.01 times, relative to the CSI 300's P/E ratio of 3.86 times [19]. 2. Industry News - Recent policy changes in Hebei Province have lifted restrictions on the quantity of drugs that hospitals can stock, allowing for more flexibility in drug procurement [24]. - The National Health Commission issued new medical treatment guidelines for trauma and burn victims to enhance emergency response capabilities [22][23]. 3. Company Announcements - Enhua Pharmaceutical announced the approval of a new drug registration certificate for a non-steroidal anti-inflammatory drug, which is expected to reduce the need for opioid pain relief post-surgery [25]. 4. Industry Outlook - The report suggests a focus on investment opportunities in the brain-computer interface sector, which is highlighted in the 14th Five-Year Plan, with ongoing policy support [26]. - Recommended stocks for attention include leading companies in medical devices, pharmaceutical retail, aesthetic medicine, and innovative drugs, among others [28].

Group 1: Gold Market Analysis - The bull market for gold is not over, with macro factors remaining optimistic and short-term fluctuations driven by geopolitical events [3][11][13] - Key macro pricing factors for gold have not changed, indicating a sustained upward potential in the medium to long term [3][13] - Micro indicators show that while gold price deviations are high, the RSI is healthy, and ETF inflows continue to rise, suggesting no clear direction for gold prices [3][13] Group 2: Semiconductor Industry Insights - TSMC's revenue for December 2025 is projected to grow by 20.4% year-on-year, driven by high-margin advanced processes and strong demand from AI/HPC sectors [4][12] - The advanced process capacity is fully loaded, with HPC accounting for 55% of revenue and 3nm technology representing 28% of wafer revenue [4][12] - TSMC's guidance for Q1 2026 indicates revenue between $34.6 billion and $35.8 billion, with a gross margin of 63%-65%, reflecting strong demand visibility in AI [4][14] Group 3: Beauty Industry Trends - The South Korean beauty market has undergone several growth and decline phases, with the current phase focusing on global market expansion and reducing reliance on China [18][20] - New brands like APR and Silicon2 are outperforming traditional giants, indicating a shift in market dynamics and consumer preferences [20] - The report highlights the importance of innovation in product formulation and packaging, with South Korean brands leading in areas like cushion packaging and functional skincare products [20]

业 研 究 / 行 业 点 相关研究 行 业 及 产 业 美容护理 2026 年 01 月 22 日 证 券 研 究 报 告 证券分析师 王立平 A0230511040052 wanglp@swsresearch.com 聂霜 A0230524120002 nieshuang@swsresearch.com 联系人 聂霜 A0230524120002 nieshuang@swsresearch.com 品牌格局重塑，全球战略扩张 看好 ——从韩国美妆发展看如何重建新增长动能 本期投资提示： 请务必仔细阅读正文之后的各项信息披露与声明 本研究报告仅通过邮件提供给 中庚基金 使用。1 ⚫ 韩国美妆市场相对成熟，进行国际化探索早，并随着自身国家综合实力、本土需求与国 际市场需求的变化，发展经历数次沉浮，其展现的发展路径值得国货公司参考借鉴。我 们通过对韩国美妆市场的研究，探索韩国美妆在不同的发展阶段，崛起的美妆集团组织 架构的特点，如何在需求端快速变化的产品领域加速推新，在新成分、新剂型等领域如 何走在全球市场前端，以及拥抱全球市场背后所需要的能力。 ⚫ 韩国美妆四大成长与衰退阶段，把握低谷紧抓转型，再临高峰。韩国 ...

Market Overview - The Shanghai Composite Index rose by 0.14% on January 22, with 22 out of the sectors in the Shenwan classification experiencing gains. The top-performing sectors were building materials and defense industry, with increases of 4.09% and 3.23% respectively [1] - Conversely, the beauty and personal care sector saw a decline of 0.76%, making it the worst-performing sector of the day [1] Capital Flow Analysis - The main capital flow showed a net outflow of 21.612 billion yuan across the two markets. However, 12 sectors experienced net inflows, with the telecommunications sector leading at a net inflow of 8.019 billion yuan and a daily increase of 2.83%. The defense industry followed with a net inflow of 5.713 billion yuan and a daily increase of 3.23% [1] - In contrast, 19 sectors faced net outflows, with the electronics sector experiencing the largest outflow of 13.206 billion yuan, followed by the power equipment sector with a net outflow of 7.206 billion yuan. Other sectors with significant outflows included non-ferrous metals, automotive, and pharmaceutical biotechnology [1] Beauty and Personal Care Sector - The beauty and personal care sector had a net outflow of 11.6 million yuan, with 29 stocks in the sector. Out of these, 9 stocks increased while 19 stocks decreased in value [2] - The stocks with the highest net inflows included Reliable Co., with a net inflow of 9.1418 million yuan, followed by Yanjiang Co. and Kesi Co., with net inflows of 8.6120 million yuan and 8.3405 million yuan respectively [2] - The stocks with the largest net outflows included Aimeike, Beitaini, and Qingdao Jinwang, with net outflows of 39.1013 million yuan, 32.7828 million yuan, and 22.1681 million yuan respectively [2] Individual Stock Performance - The top stocks in the beauty and personal care sector based on capital flow included: - Aimeike: -2.07% change with a net outflow of 39.1013 million yuan [2] - Beitaini: -1.42% change with a net outflow of 32.7828 million yuan [2] - Qingdao Jinwang: -0.85% change with a net outflow of 22.1681 million yuan [2] - Other notable stocks with significant capital flow included: - Reliable Co.: +1.62% change with a net inflow of 9.1418 million yuan [3] - Yanjiang Co.: -5.98% change with a net inflow of 8.6120 million yuan [3] - Kesi Co.: +1.29% change with a net inflow of 8.3405 million yuan [3]

Market Performance - The recombinant protein sector declined by 0.62%, ranking among the top losers in the concept sectors, with *ST WanFang hitting the daily limit down [1] - Notable declines in the sector included Aladdin, Zexing Pharmaceutical, and Shutaishen, while 18 stocks within the sector saw price increases, with Haitai Biological, Yabao Pharmaceutical, and Zhongyuan Qihe leading with gains of 4.28%, 1.17%, and 1.08% respectively [1] Capital Flow - The recombinant protein sector experienced a net outflow of 479 million yuan, with 41 stocks seeing net outflows, and 6 stocks with outflows exceeding 30 million yuan [1] - The stock with the highest net outflow was Xilong Science, with a net outflow of 59.20 million yuan, followed by Aladdin, Shutaishen, and Aimeike with outflows of 50.46 million yuan, 39.78 million yuan, and 39.10 million yuan respectively [1] Top Gainers and Losers - The top gainers in the recombinant protein sector included Haitai Biological, with a gain of 4.28%, and the top losers included Aladdin and Shutaishen, with declines of 6.46% and 2.49% respectively [1][2] - Other notable stocks with significant capital inflows included Haitai Biological, Huayu Pharmaceutical, and Tonghua Dongbao, with net inflows of 17.77 million yuan, 15.97 million yuan, and 9.97 million yuan respectively [3]

Core Viewpoint - The medical beauty sector experienced a decline of 1.35% on January 22, with Jinbo Biological leading the drop, while the overall market indices showed slight increases [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4122.58, up 0.14% - The Shenzhen Component Index closed at 14327.05, up 0.5% [1]. Group 2: Individual Stock Performance - ST Meigu closed at 3.34, with an increase of 1.52% and a trading volume of 60,900 shares, totaling a transaction value of 20.15 million yuan - Huaxi Biological closed at 45.54, down 0.76% with a trading volume of 28,800 shares, totaling a transaction value of 13.2 million yuan - Aimeike closed at 141.60, down 2.07% with a trading volume of 31,200 shares, totaling a transaction value of 44.6 million yuan - Jinbo Biological closed at 226.99, down 2.21% with a trading volume of 7,993.54 shares, totaling a transaction value of 183 million yuan [1]. Group 3: Capital Flow Analysis - The medical beauty sector saw a net outflow of 66.31 million yuan from main funds, while retail investors contributed a net inflow of 45.07 million yuan - The detailed capital flow for individual stocks shows: - ST Meigu: Main funds net inflow of 1.81 million yuan, retail net outflow of 759,000 yuan - Huaxi Biological: Main funds net outflow of 24.14 million yuan, retail net inflow of 8.44 million yuan - Jinbo Biological: Main funds net outflow of 35.10 million yuan, retail net inflow of 313,600 yuan - Aimeike: Main funds net outflow of 43.98 million yuan, retail net inflow of 37.39 million yuan [2].

Group 1 - The core point of the article is that the company Aimeike reported its shareholder count as of January 20, 2026, which stands at 61,728 households [2]

证券之星消息，1月21日，生物经济（970038）指数报收于2249.37点，涨0.3%，成交272.77亿元，换手 率2.27%。当日该指数成份股中，上涨的有28家，迪安诊断以5.59%的涨幅领涨，下跌的有22家，康弘药 业以1.78%的跌幅领跌。 生物经济（970038）指数十大成份股详情如下： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 000021 | 深科技 | 1.87亿 ﮯ | 3.06% | -9441.13万 | -1.55% | -9272.83万 | -1.52% | | 300142 | 沃森生物 | 6444.78万 | 8.62% | -3115.26万 | -4.16% | -3329.52万 | -4.45% | | 000930 | 中粮科技 | 5427.62万 | 9.84% | 491.65万 | 4 0.89% | -5919.27万 | -10.73% | | 002 ...

Group 1 - The core viewpoint of the news highlights the positive performance of the medical device sector, with significant stock price increases for various companies and a favorable market outlook driven by new pricing policies and international trade initiatives [1][2][3] Group 2 - As of January 21, the Shanghai Composite Index rose by 0.22%, while the medical device index increased by 0.69%, with notable stock performances from Tianzhihang-U (+13%), Sanyou Medical (+7%), and others [1] - The medical device ETF (562600) saw a 0.77% increase, with a trading volume of 254.268 billion yuan and a turnover rate of 4.15%. Over the past six months, the fund has gained 4.80%, and 11.30% over the past year [1] Group 3 - On January 20, the National Healthcare Security Administration issued guidelines for pricing medical services related to surgical robots and remote surgeries, establishing a structured pricing system to enhance innovation returns and improve accessibility to precision medicine [2] - A special seminar was held on January 17 to discuss how to leverage the medical device procurement and pricing platform to support the international expansion of Chinese medical devices, with plans for a cross-border channel based on procurement platforms in Guangxi and Tianjin [2] Group 4 - Multiple authoritative institutions have expressed optimism about the medical device sector, with expectations for a turning point in operations by 2026 due to optimized procurement rules and significant growth potential in domestic and international markets for surgical robots and AI medical technologies [3] - The medical device ETF (562600) tracks the CSI All Index for medical devices, with the top ten weighted stocks accounting for 45.04% of the total, including major players like Mindray Medical and United Imaging [3]